Detalhe da pesquisa
1.
BET bromodomain inhibitors regulate keratinocyte plasticity.
Nat Chem Biol
; 17(3): 280-290, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462494
2.
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Invest New Drugs
; 38(6): 1774-1783, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32410080
3.
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
J Neurooncol
; 146(1): 79-89, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31776899
4.
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.
Proc Natl Acad Sci U S A
; 114(12): 3151-3156, 2017 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28265066
5.
Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.
Blood
; 136(17): 1983-1988, 2020 10 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575123
6.
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Lung Cancer
; 192: 107820, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38763104
7.
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Cell Rep
; 42(4): 112297, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36961816
8.
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.
Blood
; 113(8): 1768-77, 2009 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-18845793
9.
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Clin Cancer Res
; 27(2): 418-428, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887722
10.
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 11(14): 1289, 2020 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292577
11.
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Oncotarget
; 11(11): 956-968, 2020 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32215184
12.
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition.
Sci Adv
; 6(25): eabb2210, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32704543
13.
New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.
ACS Med Chem Lett
; 10(12): 1655-1660, 2019 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857842
14.
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Clin Cancer Res
; 25(10): 3164-3175, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674502
15.
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
PLoS One
; 14(10): e0221635, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31600213
16.
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.
Ther Adv Med Oncol
; 11: 1758835919889001, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853265
17.
A gain-of-function mutation of JAK2 in myeloproliferative disorders.
N Engl J Med
; 352(17): 1779-90, 2005 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-15858187
18.
A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family.
Haematologica
; 93(5): 706-14, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18367486
19.
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 9(81): 35226-35240, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30443290
20.
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
ACS Med Chem Lett
; 8(3): 338-343, 2017 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28337327